Thank you very much.
To let the committee know, normally when we start into a study of this kind we have the agency, which you are, come forward and explain the situation. You have the opportunity to do that now. You couldn't make it at the beginning so you had the opportunity to address some of the questions that were brought up by previous individuals who testified before the committee. It's a bit of an advantage to you, which is fine, because we're not looking for anyone to get an advantage; we're looking for answers. So I appreciate your dealing with some of those.
With that, we'll move on to Jill Sanders, who is here with the Canadian Agency for Drugs and Technologies in Health, or CADTH. The floor is yours.